ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0170

Association of General Physical Functioning, Valued Life Activity (VLA) Disability, and Use of Accommodations with Depressive Symptoms Among Individuals with Systemic Lupus Erythematosus (SLE)

Patti Katz1, Laura Plantinga2, Maria Dall'Era3, Kamil Barbour4, Kurt Greenlund4 and Jinoos Yazdany5, 1UCSF, San Rafael, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, Corte Madera, CA, 4CDC, Alpharetta, GA, 5University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2024

Keywords: depression, physical function, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Physical functioning (PF) is usually assessed generally in SLE rather than as difficulty performing specific activities, and measurements rarely incorporate accommodations (ACCs) that may be used to maintain the ability to perform activities. Research in other conditions has shown that disability in valued life activities (VLAs) is more closely related to depression than is general PF. We examined difficulty in performing VLAs, ACCs used in for VLAs, and the associations of general PF, VLA difficulty, and ACC use with depressive symptoms.

Methods: Data were from Year 7 of the California Lupus Epidemiology Study (CLUES), a longitudinal cohort with physician-confirmed SLE (n=302). General PF was measured with PROMIS Physical Function 10a (PF10). VLA difficulty was measured with the Short Valued Life Activities disability scale (SVLA), in which the difficulty of 17 items in 3 categories (Obligatory [necessary for survival and self-sufficiency], Committed [associated with principal productive roles], and Discretionary [for relaxation or pleasure])1 is rated (0, no difficulty, to 3, unable to perform).  Scores are the mean of all rated items. For each item, individuals were also asked if they used any of the following strategies to help perform an activity:  Limit the time or the frequency of performing; perform more slowly or take more time; need help from another person; or any other changes or accommodations. Patient Health Questionnaire (PHQ)-8 assessed depressive symptoms. Mean difficulty and ACC use for each VLA, as well as for activity types and overall, were tabulated.  Linear regression assessed associations of PF10, VLA difficulty, and ACC use with PHQ-8 individually and concurrently in unadjusted and adjusted (age, sex, race, income, disease duration, glucocorticoid use≥7.5 mg/day) models.

Results: Cohort characteristics are shown in Table 1. The overall SVLA score was 0.49 ± 0.56. Difficulty ratings were generally higher for Committed and Discretionary activities than for Obligatory activities (Table 2). At least 1 in 5 used some type of ACC for each VLA. Respondents were more likely to limit Discretionary activities than other types of activities and more likely to need help for Committed activities. PF10, SVLA, and ACCs were each significantly associated with depressive symptoms in individual and combined models (Table 3). However, SVLA had a stronger association with depression than PF10 or ACCs in concurrent models.

Conclusion: Difficulties performing VLAs is common among people with SLE, and most used at least one ACC. Patterns of ACCs suggest that people may be more likely to limit performance of Discretionary activities and seek help for Committed activities. Even controlling for general PF, VLA difficulty is strongly associated with depressive symptoms, suggesting the important role of maintaining VLAs to psychological well-being.  Even though ACC use may allow individuals to maintain VLAs, greater use of ACCs was also associated with depressive symptoms.  Findings underscore the importance of helping individuals maintain valued activities even in the presence of functional limitations.

1Verbrugge L, Jette A. Soc Sci Med 1994;38:1-14.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Katz: None; L. Plantinga: None; M. Dall'Era: AstraZeneca, 2, Aurinia, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2; K. Barbour: None; K. Greenlund: None; J. Yazdany: AstraZeneca, 2, Aurinia, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, UCB, 2.

To cite this abstract in AMA style:

Katz P, Plantinga L, Dall'Era M, Barbour K, Greenlund K, Yazdany J. Association of General Physical Functioning, Valued Life Activity (VLA) Disability, and Use of Accommodations with Depressive Symptoms Among Individuals with Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-of-general-physical-functioning-valued-life-activity-vla-disability-and-use-of-accommodations-with-depressive-symptoms-among-individuals-with-systemic-lupus-erythematosus-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-general-physical-functioning-valued-life-activity-vla-disability-and-use-of-accommodations-with-depressive-symptoms-among-individuals-with-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology